Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-κB.

doi:10.1016/j.biopha.2017.11.022

Paper

Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-κB.

Published Nov 22, 2017 · Shu-zhai Han, Hong-xia Liu, Lin-Qing Yang

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Q1 SJR score

43

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Rigorous Journal

Study Snapshot

Piperine enhances mitomycin-C therapy in human cervical cancer by suppressing Bcl-2 signaling and inactivating STAT3/NF-B, potentially reversing drug resistance.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-κB.

References

Citations